ENHANCED EXPANSION OF CULTURED HEMATOPOIETIC STEM

增强培养造血干细胞的扩增

• 批准号: 2371389
• 负责人: JEFFREY A GREENSPAN
• 金额: $ 10万
• 依托单位: MUNIN CORPORATION
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-09-30 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/2371389
• 关键词: ENHANCED; EXPANSION; CULTURED; HEMATOPOIETIC; STEM

For clinical patients with suppressed hematopoiesis, introduction of autologous hematopoietic stem cells (HSC) that can be manipulated and expanded in culture would be very beneficial. However, primitive HSC with pluripotent potential and long term repopulating ability are presently difficult to maintain in culture; they tend to mature into lineage- committed progenitors. The long term goal of this proposal is to demonstrate that the recently characterized mammalian protein Cyr61, a recombinant form of which can be purified in large quantities, will enhance expansion of pluripotent human HSC in culture. The short term goal is to investigate whether murine Cyr61 can function as a supplement to a murine HSC culture system. The specific aims and design of the project will be to establish long term murine HSC cultures with or without supplemental Cyr61, and assay the populations of these cultures for growth rate, and relative proportions of immature stem cells and more mature progenitors. Demonstration of the ability of Cyr61 to enhance expansion of HSC in culture would lead to attempts to use these cells to effect in vivo hematopoietic repopulation in Phase II.

对于临床上造血抑制的患者，引入 可以被操纵的自体造血干细胞（HSC） 文化上的扩展将是非常有益的。然而，原始 HSC 具有 多能潜力和长期再生能力目前 难以在文化中维持；他们倾向于成熟为血统- 承诺的祖先。该提案的长期目标是 证明最近鉴定的哺乳动物蛋白 Cyr61 其重组形式可以大量纯化，将 增强多能人类 HSC 在培养物中的扩增。短期 目标是研究鼠 Cyr61 是否可以作为补充剂 小鼠 HSC 培养系统。具体目标和设计 项目将建立长期的鼠 HSC 培养物或 无需补充 Cyr61，并测定这些培养物的群体 生长速度、未成熟干细胞的相对比例等 成熟的祖细胞。 Cyr61增强能力展示 HSC 在培养物中的扩增将导致尝试使用这些细胞 影响体内造血再生的第二阶段。